Randomised multicentre trial on safety and efficacy of rivastigmine in cognitively impaired MS patients

This study from Germany carried out a multicentre, double-blind, randomised, placebo-controlled study, on the safety and efficacy of rivastigmine in cognitively impaired MS patients. 86 patients were enrolled in the study. Primary endpoints included the change in total recall scores of the selective reminding test (SRT) from baseline to 16 weeks.

Overall, they found that there was a tendency for improvement of total recall by rivastigmine, however, this was not siginificant because of lack of statistical power. Other outcome measures provided no evidence supporting benefits of rivastigmine over placebo. Treatment with rivastigmine was safe and well tolerated.

Authors:
Mäurer M, Ortler S, Baier M

Source:
Mult Scler. 2012 Oct 15. [Epub ahead of print]

Read the abstract

 

Latest MS research news

Main MS research areas

Challenges of MS research